Trump's Mental-Health Concern Trolling Won't End Mass Shootings

Nyloxin Rx, which was developed by Nutra Pharma's drug discovery subsidiary, ReceptoPharm, is a prescription medicine launching in late-2009 for the treatment of severe (Stage 3) chronic pain.

Nutra Pharma Corp, a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.

Nyloxin Rx is a prescription pain reliever produced by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating Stage 3 pain, which is the most severe pain that inhibits one's ability to fully function. Additionally, Nyloxin Rx does not rely on the use of opioids for its pain relieving action, but, instead, uses a novel mechanism from cobra venom peptides for treating pain